|Original language||English (US)|
|Number of pages||2|
|Journal||Journal of Allergy and Clinical Immunology: In Practice|
|State||Published - Sep 1 2016|
ASJC Scopus subject areas
- Immunology and Allergy
Access to Document
Other files and links
In: Journal of Allergy and Clinical Immunology: In Practice, Vol. 4, No. 5, 01.09.2016, p. 1019-1020.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Reply
AU - Bonilla, Francisco A.
AU - Chapel, Helen
AU - Costa-Carvalho, Beatriz T.
AU - Cunningham-Rundles, Charlotte
AU - de la Morena, M. Teresa
AU - Espinosa-Rosales, Francisco J.
AU - Hammarström, Lennart
AU - Nonoyama, Shigeaki
AU - Quinti, Isabella
AU - Routes, John M.
AU - Tang, Mimi L K
AU - Warnatz, Klaus
N1 - Funding Information: Conflicts of interest: F. A. Bonilla has received consultancy fees from Baxalta, The Cowen Group, CSL Behring, US Food and Drug Administration, Gerson-Lehrman Group, Grand Rounds Health, Grifols, Harvard Pilgrim Health Care, and the Immune Deficiency Foundation; has received research support from CSL Behring; has received lecture fees from Finger Lakes Allergy Society and the University of Rochester Medical Center; and receives royalties from UpToDate in Medicine. H. Chapel has received consultancy fees from Biotest; has received lecture fees from Grifols; and has received payment for development of educational presentations from Baxalta. B. T. Costa-Carvalho has received consultancy fees from Baster-Brasil; has received research support from Fundacao de Amparo a Pesquisa Sao Paulo; and has received lecture fees from CSL-Brasil. M. T. de la Morena was a member of the Atlantic Research Group (KB052 Data Safety Monitoring Board in conjunction with Data Safety Monitoring Board charter) and has received research support from the Jeffrey Modell Foundation. F. J. Espinosa-Rosales is on the Baxalta Board; has received lecture fees from CSL Behring, Baxalta, Octapharma, and Nestle; and has received travel support from CSL Behring and Octapharma. L. Hammarström has received research support from Baxalta; and has received travel support from CSL Behring. I. Quinti is on the Baxalta and CSL Behring boards; has received lecture fees from Baxalta, CSL Behring, and Kedrion. K. Warnatz is on the Boards for Biotest, CSL Behring, and LFB Biomedicaments; has received research support from Bristol-Myers Squibb, CSL Behring, and Biotest; has received lecture fees from LFB Biomedicaments, Baxter, GlaxoSmithKline, CSL Behring, Pfizer, Biotest, Novartis Pharma, Roche, Meridian Health, and Octapharma; and has received payment for manuscript preparation from UCB Pharma. The rest of the authors declare that they have no relevant conflicts.
PY - 2016/9/1
Y1 - 2016/9/1
UR - http://www.scopus.com/inward/record.url?scp=84992125279&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84992125279&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2016.04.029
DO - 10.1016/j.jaip.2016.04.029
M3 - Letter
C2 - 27587326
AN - SCOPUS:84992125279
SN - 2213-2198
VL - 4
SP - 1019
EP - 1020
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 5